These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 11872871)

  • 21. Nevirapine or efavirenz combined with two nucleoside reverse transcriptase inhibitors compared to HAART: a meta-analysis of randomized clinical trials.
    Torre D; Tambini R; Speranza F
    HIV Clin Trials; 2001; 2(2):113-21. PubMed ID: 11590519
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Results of the AIDS-In-Europe Study. Non-nucleoside reverse transcriptase inhibitor does not equal non-nucleoside reverse transcriptase inhibitor].
    MMW Fortschr Med; 2001 Apr; 143 Suppl 1():39. PubMed ID: 11373776
    [No Abstract]   [Full Text] [Related]  

  • 23. Plasma lipid concentrations after 1.5 years of exposure to nevirapine or efavirenz together with stavudine and lamivudine.
    van Leth F; Hall DB; Lange JM; Reiss P
    HIV Med; 2006 Sep; 7(6):347-50. PubMed ID: 16903977
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes.
    Chiesa E; Bini T; Adorni F; Capetti A; Rizzardini G; Faggion I; Mussini C; Sollima S; Melzi S; Bongiovanni M; Tordato F; Cicconi P; Castelnuovo B; Rusconi S; d'Arminio Monforte A
    Antivir Ther; 2003 Feb; 8(1):27-35. PubMed ID: 12713061
    [TBL] [Abstract][Full Text] [Related]  

  • 25. What they say about non-nucleoside drugs.
    Posit Aware; 1999; 10(1):35-7. PubMed ID: 11366521
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Report from the Tenth Retrovirus Conference. Comparing efavirenz and nevirapine: the 2NN study.
    Sax PE
    AIDS Clin Care; 2003 Apr; 15(4):32. PubMed ID: 12712946
    [No Abstract]   [Full Text] [Related]  

  • 27. Nevirapine found to be as effective as efavirenz.
    TreatmentUpdate; 2003; 15(2):3-4. PubMed ID: 12693360
    [No Abstract]   [Full Text] [Related]  

  • 28. Comparative biological and clinical outcomes after a switch from a virologically unsuccessful first protease inhibitor-containing antiretroviral combination to a 3-drug regimen containing efavirenz, nevirapine, or abacavir.
    Abgrall S; Yeni PG; Bouchaud O; Costagliola D;
    Clin Infect Dis; 2007 Jan; 44(1):120-7. PubMed ID: 17143827
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efavirenz: resistance and cross-resistance.
    Clotet B
    Int J Clin Pract Suppl; 1999 Jun; 103():21-5. PubMed ID: 10622039
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HIV infection.
    Talbot M
    Clin Evid; 2005 Dec; (14):802-17. PubMed ID: 16620438
    [No Abstract]   [Full Text] [Related]  

  • 31. Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy.
    Parienti JJ; Massari V; Descamps D; Vabret A; Bouvet E; Larouzé B; Verdon R
    Clin Infect Dis; 2004 May; 38(9):1311-6. PubMed ID: 15127346
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of nevirapine- and efavirenz-containing antiretroviral regimens in antiretroviral-naïve patients: a cohort study.
    Keiser P; Nassar N; White C; Koen G; Moreno S
    HIV Clin Trials; 2002; 3(4):296-303. PubMed ID: 12187503
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a systematic review and meta-analysis.
    Jiang HY; Zhang MN; Chen HJ; Yang Y; Deng M; Ruan B
    Int J Infect Dis; 2014 Aug; 25():130-5. PubMed ID: 24911886
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Non-nucleoside reverse transcriptase inhibitors--an overview.
    Bell C; Matthews GV; Nelson MR
    Int J STD AIDS; 2003 Feb; 14(2):71-7. PubMed ID: 12662384
    [No Abstract]   [Full Text] [Related]  

  • 35. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection.
    Martínez E; Arnaiz JA; Podzamczer D; Dalmau D; Ribera E; Domingo P; Knobel H; Riera M; Pedrol E; Force L; Llibre JM; Segura F; Richart C; Cortés C; Javaloyas M; Aranda M; Cruceta A; de Lazzari E; Gatell JM;
    N Engl J Med; 2003 Sep; 349(11):1036-46. PubMed ID: 12968087
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The nonnucleoside reverse transcriptase inhibitors efavirenz and nevirapine in the treatment of HIV.
    Sheran M
    HIV Clin Trials; 2005; 6(3):158-68. PubMed ID: 16192249
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safe substitution for efavirenz.
    AIDS Patient Care STDS; 2004 Jan; 18(1):58. PubMed ID: 15080097
    [No Abstract]   [Full Text] [Related]  

  • 38. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1.
    van Leth F; Phanuphak P; Stroes E; Gazzard B; Cahn P; Raffi F; Wood R; Bloch M; Katlama C; Kastelein JJ; Schechter M; Murphy RL; Horban A; Hall DB; Lange JM; Reiss P
    PLoS Med; 2004 Oct; 1(1):e19. PubMed ID: 15526045
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine and/or efavirenz.
    van Leth F; Conway B; Laplumé H; Martin D; Fisher M; Jelaska A; Wit FW; Lange JM;
    Antivir Ther; 2004 Oct; 9(5):721-8. PubMed ID: 15535409
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial.
    Bonnet M; Bhatt N; Baudin E; Silva C; Michon C; Taburet AM; Ciaffi L; Sobry A; Bastos R; Nunes E; Rouzioux C; Jani I; Calmy A;
    Lancet Infect Dis; 2013 Apr; 13(4):303-12. PubMed ID: 23433590
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.